

**Oregon Board of Pharmacy**  
**STRATEGIC PLANNING MEETING AGENDA**  
**November 8-9, 2023**

**Public Attendance Options:**

1. In-person: [Oregon Coast Aquarium](#) – Gleason Room 2820 SE Ferry Slip Rd. Newport, OR 97365
2. \*If you plan on attending in person, please arrive at the Aquarium after 8:00AM but no later than 8:30AM and check in at Admissions.
  - a. If you arrive between 8:30AM-10:00AM and are unable to access the Aquarium, email your contact information and state that you are attending the Oregon Board of Pharmacy Strategic Planning Meeting to [Lisa.White@Aquarium.org](mailto:Lisa.White@Aquarium.org) and staff will meet you at the front entrance.  
\*Please note that the Aquarium isn't open to the general public until 10:00AM and the doors will be locked.
3. Virtually via Teams: [Link](#)
4. Audio only: (503) 446-4951 Phone Conference ID: 488 574 041#
5. *If you experience audio issues upon joining the virtual meeting, send an email to [pharmacy.board@bop.oregon.gov](mailto:pharmacy.board@bop.oregon.gov) for assistance*

*The Oregon Board of Pharmacy serves to promote and protect public health, safety, and welfare by ensuring high standards in the practice of pharmacy and through effective regulation of the manufacture and distribution of drugs.*

**Wednesday, November 8, 2023 @ 8:30AM**

**Thursday, November 9, 2023 @ 8:30AM**

- All OBOP meetings, except Executive Sessions, are open to the public. Pursuant to ORS 192.660(1)(2)(f)(L), Executive Sessions are closed to the public, with the exception of news media and public officials
- No final actions will be taken in Executive Session
- When action is necessary, the board will return to Open Session
- To sign up for Public Comment, email your request to [pharmacy.board@bop.oregon.gov](mailto:pharmacy.board@bop.oregon.gov) by **10:00AM on 11/9/2023**

*If you need accommodations under the Americans with Disabilities Act (ADA), complete and submit the online [OBOP Request for ADA Accommodations for Public Meetings form](#) located on our website.*

**WEDNESDAY, NOVEMBER 8, 2023**

**I. OPEN SESSION, Ian Doyle RPh, Presiding**

**\*PLEASE NOTE THERE MAY BE TIMES DURING THIS MEETING IN WHICH THE BOARD MAY DIVIDE INTO SMALL GROUPS AND IT MAY BE DIFFICULT FOR VIRTUAL ATTENDEES TO HEAR. WE ENCOURAGE THE PUBLIC TO ATTEND IN PERSON TO BE ABLE TO HEAR AND OBSERVE WHAT OCCURS DURING THESE PORTIONS OF THE MEETING.\***

- a. Roll Call

**Oregon Board of Pharmacy**  
**STRATEGIC PLANNING MEETING AGENDA**  
**November 8-9, 2023**

- b. Agenda Review and Approval

*Action Necessary*

**II. STRATEGIC PLANNING – Part One**

- a. Ground Rules & Board Responsibilities
- b. Progress, Current Issues & Trends
  - i. Strategic & Performance Review – *Schnabel/Doyle*
  - ii. Agency Assessment Findings
  - iii. Review/Potential Adjustment of Strategic Plan “Pillars”
  - iv. Pillars and SWOT Round-Robin group idea sharing
- c. Priority Evaluation & Direction
  - i. Licensees
  - ii. Technology
  - iii. Licensing & Registration
- d. Working to Consensus
  - i. Defining consensus and discussion on reaching agreement
- e. Mission, Vision and Values
  - i. Review, assessment and recommitment

Adjourn

*Action Necessary*

**THURSDAY, NOVEMBER 9, 2023**

**I. OPEN SESSION, Ian Doyle RPh, Presiding**

**\*PLEASE NOTE THERE MAY BE TIMES DURING THIS MEETING IN WHICH THE BOARD MAY DIVIDE INTO SMALL GROUPS AND IT MAY BE DIFFICULT FOR VIRTUAL ATTENDEES TO HEAR. WE ENCOURAGE THE PUBLIC TO ATTEND IN PERSON TO BE ABLE TO HEAR AND OBSERVE WHAT OCCURS DURING THESE PORTIONS OF THE MEETING.**

- a. Roll Call

**II. STRATEGIC PLANNING – Part Two**

- a. Priority Evaluation and Direction – Continued
  - i. Regulation
  - ii. Compliance
  - iii. Communication

**III. DIVERSITY, EQUITY and INCLUSION**

- a. Review of current state, perspectives and opportunities
- b. Evaluate/define areas of impact, influence and action
- c. Identify Next Steps

**IV. PUBLIC COMMENT - 1:00PM**

**Oregon Board of Pharmacy**  
**STRATEGIC PLANNING MEETING AGENDA**  
**November 8-9, 2023**

**V. STRATEGIC PLANNING – Part Three**

- a. Full Board review and comment on priority direction and goals
- b. Meeting assessment
- c. Final comments from Board President and Executive Director

Adjourn

*Action Necessary*